|
An Improved Prostate Biomarker Test May Help Men Avoid Unnecessary Biopsy
NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Newsletter
 |
|
The April 2024 edition of the NCI CAP-IT Newsletter is now available. Learn about investigator news, the latest publications, grants and awards, the CAP-IT Annual Summit, job opportunities, upcoming events, and more.
Read the CAP-IT Newsletter.
|
ULACNet Update – April 2024
|
Highlights from the latest edition of ULACNet Update, a newsletter with programmatic and research updates from the US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet), include:
- A recap from connecting and presenting at EUROGIN 2024.
- Challenges and solutions for carrying out multicenter clinical trials in Mexico.
- Completion of enrollment of the OPTIMO study in Peru, Brazil, and Haiti.
Read more in ULACNet Update.
|
|
 |
|
|
DCP Early Career Scientist Spotlight Research Seminar Series
Wednesday, May 29
Noon-1:00 p.m. ET
Advance registration required
Chemtai Mungo, M.D., M.P.H., assistant professor of obstetrics and gynecology at University of North Carolina-Chapel Hill, will give a talk titled, “Feasibility of Self-Administered, Intravaginal Therapies for Cervical Precancer Treatment in Low- and Middle-Income Countries.”
Learn more about the seminar series.
|
Division of Cancer Prevention Immunology Interest Group Seminar Series (DCP-IIG): Dr. Drew Weissman Speaks about Nucleoside Modified mRNA-LNP Therapeutics
Wednesday, June 12
3:00-4:00 p.m. ET
Advance registration required
Drew Weissman, M.D., Ph.D., a world-renowned physician and researcher at Penn Medicine, will give a talk on nucleoside modified mRNA-LNP therapeutics in cancer research, as part of the NCI DCP IIG. In 2023, Dr. Weissman, along with Dr. Katalin Kariko, received the Nobel Prize in Physiology for mRNA vaccine discoveries that led to effective COVID vaccines.
Learn more about the seminar.
|
Building Bridges in Cancer Symptom Science: Methods and Techniques for Clinical and Preclinical Chemotherapy-induced Peripheral Neuropathy (CIPN) Research
Tuesday, June 18
3:00-4:00 p.m. ET
Advance registration required
In this webinar, Paola Alberti (pictured left), M.D., Ph.D., from the School of Medicine and Surgery at University of Milano-Bicocca, will discuss methods for studying chemotherapy-induced peripheral neuropathy (CIPN) in preclinical studies and building collaborative translational teams. Ellen M. Lavoie Smith (pictured right), Ph.D., M.S.N., R.N., AOCN®, FAAN, from the University of Alabama at Birmingham School of Nursing, will then address methods and techniques for assessing CIPN in clinical trials.
Learn more about the webinar series.
|
|
|
Notice of Funding Opportunities (NOFOs): Cancer Prevention Career Development |
|
NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12)
NCI invites applications to support the training of clinical scientists in community cancer prevention, screening, intervention, control, and treatment research. Special emphasis is placed on training clinical scientists whose career goal is to improve the care and outcomes of minority health populations and populations with health disparities that are underrepresented in clinical research by increasing patient access to and representation in cancer clinical trials.
PAR-24-153
Expires: February 19, 2027
|
Notice of Special Interest: National Cancer Institute Supports Applications for the Mentored Research Scientist Development Awards (K01) Within the Mission of the Division of Cancer Prevention
This Notice of Special Interest (NOSI) from NCI encourages applications from early career scientists conducting early translational research in cancer prevention, interception, screening, and early detection within the mission of DCP for the Mentored Research Scientist Development Award (K01).
NOT-CA-24-023
Expires: May 8, 2029
|
NOSI: Administrative Supplements to Support Collection of Spanish Normative Data and Determination of Test-Retest Reliability Estimates of Neuropsychological Tests for NCI Clinical Trials
 |
|
This NOSI aims to enhance the diversity of Spanish speakers participating in NCI clinical trials that are assessing cognitive function. NCI encourages applications focused on normative data collection (data that characterize what is usual in a defined population at a specific point or period of time) and determination of test-retest reliability estimates of US-Spanish translated neuropsychological tests.
NOT-CA-24-040
Expires: June 22, 2024
|
NOSI: Administrative Supplement to Support the NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Research
NCI invites applications from current NIH grant awardees or cooperative agreement program participants interested in collaborating with the NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Specialized Centers to support CAP-IT Program research. All potential applicants are encouraged to contact the NCI Program Directors to discuss the planned collaboration and application.
NOT-CA-24-047
Expires: June 14, 2024
|
|
|
Cancer Prevention Research Conference
Tuesday, June 25-Thursday, June 27
Boston, MA
Advance registration required
The American Cancer Society, NCI, and Cancer Research UK are launching their first annual conference on prevention research that aims to create a multidisciplinary cancer prevention research community, spark new collaborations and ideas, and advance cancer prevention.
Registration deadline: June 11
For more information, including meeting agenda, speakers, and hotel, visit the Cancer Prevention Research Conference event website.
|
In case you missed it:
Read more DCP Updates.
Do you forward DCP Updates to others?
Encourage them to subscribe.
|
|
|
|
|
